Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free ... NASDAQ MORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) --Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune ... |
